Rafael Ríos Tamayo

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

María‐Victoria Mateos, Joaquín Martínez‐López, Paula Rodríguez‐Otero et al. · Blood · 2019 · 62 citations

Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial

Laura Rosiñol, Albert Oriol, Rafael Ríos Tamayo et al. · Blood · 2021 · 23 citations

Clinical significance of MUC1, MUC2 and CK17 expression patterns for diagnosis of pancreatobiliary arcinoma

HS Yang, Rafael Ríos Tamayo, Maribel Almonte et al. · Biotechnic & Histochemistry · 2011 · 16 citations

Tumor Biology, Tumoral Pathology, Pancreatic Cancer +15

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma

Laura Rosiñol, Benjamin Hébraud, Albert Oriol et al. · Frontiers in Oncology · 2023 · 16 citations · Full text

Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant of hematopoietic progenitor cells

Antonio Olry de Labry Lima, Vicente Gimeno‐Ballester, Rafael Ríos Tamayo et al. · Bone Marrow Transplantation · 2019 · 10 citations

Hematological Malignancy, Oncology, Marrow Transplantation +10